Neutrophil-to-lymphocyte Ratio (NLR) as a predictor for recurrence in patients with stage III melanoma

被引：48

作者：

Ma, Junjie ^{[1
]}

Kuzman, James ^{[2
]}

Ray, Abhijit ^{[3
]}

Lawson, Benjamin O. ^{[4
]}

Khong, Brian ^{[5
]}

Xuan, Si ^{[6
]}

Hahn, Andrew W. ^{[7
]}

Khong, Hung T. ^{[8
]}

机构：

[1] Univ Utah, Coll Pharm, Dept Pharmacotherapy, Salt Lake City, UT 84112 USA

[2] Sanford USD Med Ctr, Sioux Falls, SD USA

[3] Univ Utah, Huntsman Canc Inst, Div Oncol, Salt Lake City, UT USA

[4] HonorHealth Scottsdale Shea Med Ctr, Scottsdale, AZ USA

[5] Adventist Hlth White Mem, Los Angeles, CA USA

[6] Univ So Calif, Leonard D Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA USA

[7] Univ Utah, Sch Med, Dept Internal Med, Salt Lake City, UT USA

[8] H Lee Moffitt Canc Ctr & Res Inst, Dept Breast Oncol, Tampa, FL 33612 USA

来源：

SCIENTIFIC REPORTS | 2018年 / 8卷

关键词：

PREOPERATIVE NEUTROPHIL; RISK; RESECTION; SURVIVAL; IPILIMUMAB; MARKER;

D O I：

10.1038/s41598-018-22425-3

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Neutrophil-to-lymphocyte ratio is a strong predictor for overall survival and disease free survival in many cancers. Our study is the first investigation aiming to determine the predictive value of neutrophil-to-lymphocyte ratio on prognosis of patients with stage III melanoma. This retrospective study utilized a cohort of 107 patients with stage III melanoma treated at Huntsman Cancer Institute, University of Utah, from May 2002 to March 2016. The optimal cutoff of neutrophil-to-lymphocyte ratio was determined by the significance of log-rank tests. A total of 97 log-rank tests were conducted to find the optimal cutoff. Disease free survival was assessed using the Kaplan-Meier method, and univariable and multivariable Cox models were applied to evaluate the predictive value of neutrophil-to-lymphocyte ratio. 2.5 was identified as the optimal cutoff. Kaplan-Meier curve showed that the disease free survival rate of the low value group was significantly higher compared to that of high value group. After adjusting for confounders and other prognostic factors, the neutrophil-to-lymphocyte ratio >= 2.5 remained a strong predictor for disease recurrence in patients with stage III melanoma.

引用

页数：6

共 24 条

[1] Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients [J].

Azab, Basem ;

Shah, Neeraj ;

Radbel, Jared ;

Tan, Pamela ;

Bhatt, Vijaya ;

Vonfrolio, Steven ;

Habeshy, Ayman ;

Picon, Antonio ;

Bloom, Scott .

MEDICAL ONCOLOGY, 2013, 30 (01)

[2] Usefulness of the Neutrophil-to-Lymphocyte Ratio in Predicting Short- and Long-Term Mortality in Breast Cancer Patients [J].

Azab, Basem ;

Bhatt, Vijaya R. ;

Phookan, Jaya ;

Murukutla, Srujitha ;

Kohn, Nina ;

Terjanian, Terenig ;

Widmann, Warren D. .

ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (01) :217-224

[3] Final Version of 2009 AJCC Melanoma Staging and Classification [J].

Balch, Charles M. ;

Gershenwald, Jeffrey E. ;

Soong, Seng-jaw ;

Thompson, John F. ;

Atkins, Michael B. ;

Byrd, David R. ;

Buzaid, Antonio C. ;

Cochran, Alistair J. ;

Coit, Daniel G. ;

Ding, Shouluan ;

Eggermont, Alexander M. ;

Flaherty, Keith T. ;

Gimotty, Phyllis A. ;

Kirkwood, John M. ;

McMasters, Kelly M. ;

Mihm, Martin C., Jr. ;

Morton, Donald L. ;

Ross, Merrick I. ;

Sober, Arthur J. ;

Sondak, Vernon K. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6199-6206

[4]

Bhat T, 2013, EXPERT REV CARDIOVAS, V11, P55, DOI [10.1586/ERC.12.159, 10.1586/erc.12.159]

[5]

Bosserhoff A., 2017, MELANOMA DEV, P1, DOI DOI 10.1007/978-3-319-41319-8_1

[6] Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis [J].

Bowen, Randy C. ;

Little, Nancy Ann B. ;

Harmer, Joshua R. ;

Ma, Junjie ;

Mirabelli, Luke G. ;

Roller, Kyle D. ;

Breivik, Andrew Mackay ;

Signor, Emily ;

Miller, Alec B. ;

Khong, Hung T. .

ONCOTARGET, 2017, 8 (19) :32171-32189

[7] Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization [J].

Budczies, Jan ;

Klauschen, Frederick ;

Sinn, Bruno V. ;

Gyoerffy, Balazs ;

Schmitt, Wolfgang D. ;

Darb-Esfahani, Silvia ;

Denkert, Carsten .

PLOS ONE, 2012, 7 (12)

[8] Elevated Blood Neutrophil-to-Lymphocyte Ratio: A Readily Available Biomarker Associated with Death due to Disease in High Risk Nonmetastatic Melanoma [J].

Davis, Jeremy L. ;

Langan, Russell C. ;

Panageas, Katherine S. ;

Zheng, Junting ;

Postow, Michael A. ;

Brady, Mary S. ;

Ariyan, Charlotte ;

Coit, Daniel G. .

ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (07) :1989-1996

[9] Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial [J].

Eggermont, Alexander M. M. ;

Chiarion-Sileni, Vanna ;

Grob, Jean-Jacques ;

Dummer, Reinhard ;

Wolchok, Jedd D. ;

Schmidt, Henrik ;

Hamid, Omid ;

Robert, Caroline ;

Ascierto, Paolo A. ;

Richards, Jon M. ;

Lebbe, Celeste ;

Ferraresi, Virginia ;

Smylie, Michael ;

Weber, Jeffrey S. ;

Maio, Michele ;

Konto, Cyril ;

Hoos, Axel ;

de Pril, Veerle ;

Gurunath, Ravichandra Karra ;

de Schaetzen, Gaetan ;

Suciu, Stefan ;

Testori, Alessandro .

LANCET ONCOLOGY, 2015, 16 (05) :522-530

[10] Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients [J].

Ferrucci, P. F. ;

Gandini, S. ;

Battaglia, A. ;

Alfieri, S. ;

Di Giacomo, A. M. ;

Giannarelli, D. ;

Cappellini, G. C. Antonini ;

De Galitiis, F. ;

Marchetti, P. ;

Amato, G. ;

Lazzeri, A. ;

Pala, L. ;

Cocorocchio, E. ;

Martinoli, C. .

BRITISH JOURNAL OF CANCER, 2015, 112 (12) :1904-1910

← 1 2 3 →